Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Pro-inflammatory diet ups risk oral cancer

10 Jul 2020

A diet that is considered pro-inflammatory appears to increase the risk of oral cancer, according to a recent study in Fujian Province, China.

The authors performed a case-control study to assess the role of the potential inflammatory effects of diet using the Energy-adjusted Dietary Inflammatory Index (E-DII) for oral cancer. They included 295 oral cancer patients and 425 control from Fujian Province from September 2010 to June 2018.

The E-DII was calculated based on the food frequency questionnaire (FFQ) and adjusted by total energy intake. Unconditional logistic regression model was used to estimate the association between E-DII and the risk of oral cancer.

Participants with E-DII score in the highest quartile had a greater risk of oral cancer (odds ratio, 2.57, 95 percent CI, 1.54–4.29; ptrend=0.013) compared to those with E-DII score in the lowest quartile. When analyses were done using E-DII as a continuous variable, a one-unit increase in E-DII led to a 3-percent increase in the risk of having oral cancer (95 percent CI, 1.00–1.06).

In addition, a significant association was observed between the E-DII and oral hygiene for oral cancer (pinteraction<0.001 in those without and with poor hygiene; OR, 1.96, 95 percent CI, 0.96–4.00 and OR, 4.23, 95 percent CI, 1.83–9.81, respectively).

“More large samples and prospective studies need to validate our results and explore the prevention strategies of oral cancer via changing dietary habits,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.